Cytosolic DNA is the Link Between Genomic Instability and Cardiovascular Aging
细胞质 DNA 是基因组不稳定性与心血管衰老之间的联系
基本信息
- 批准号:10722123
- 负责人:
- 金额:$ 61.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-15 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AgingAntibodiesAttenuatedAutophagocytosisBiological ProcessCCCTC-binding factorCardiacCardiac MyocytesCardiovascular systemCell AgingCell DeathCell NucleusCellsCodeCytoplasmCytosolDNADNA Double Strand BreakDNA Transposable ElementsDefectEndothelial CellsEpigenetic ProcessEventFibroblastsFibrosisGene ExpressionGenesGeneticGenome StabilityGenomic InstabilityGoalsHeartHistone DeacetylaseHumanIRF3 geneImpairmentInflammationInflammatoryKnock-inLamin Type ALengthLinkLogicMapsMechanicsMethylationMitochondriaMitochondrial DNAMolecularMorbidity - disease rateMutationNF-kappa BNuclearNuclear EnvelopeOrganOrganismPathogenesisPathway interactionsPhenotypePremature aging syndromeProteinsResolutionRoleSTING1 geneSirtuinsSiteSourceSpliced GenesTBK1 geneTestingTranscription Initiation SiteWild Type Mouseage relatedcell typechromatin immunoprecipitationcohesincytokinedesigndetection of nutrientenv Gene Productsgenome integritygenome-wideheart cellheart functioninsightmortalitymouse modelnormal agingprematureprototyperepairedsenescencestem cell self renewaltelomeretranscriptome sequencing
项目摘要
Premature aging syndromes in laminopathies caused by mutations in the LMNA gene, encoding nuclear
envelope protein lamin A/C (LMNA), are the prototypic examples of genomic instability, which is a hallmark of
“normal” aging. Cardiovascular involvement is the cardinal phenotype and the major cause of mortality and
morbidity. The pathogenesis of laminopathies and “normal” aging share several common mechanisms. LMNA
regulates mitochondrial function, telomere length, nutrient sensing, stem cell regeneration, and autophagy, which
are the classic hallmarks of “normal aging”. LMNA expression is reduced in “normal” aging. A similar set of
nuclear defects are observed in “normal” aging and laminopathies. LMNA also regulates several epigenetic
regulators of aging, including sirtuins and histone deacetylases. Furthermore, LMNA is essential for genomic
instability and induction and repair of the double-stranded DNA breaks (DSBs) as well as the mechanical integrity
of the nuclear membrane. These mechanisms are also the core mechanisms of “normal” aging.
We have shown that the cytosolic DNA (CyDNA)-sensing proteins CGAS/STING1 are induced and their
downstream effectors TBK1, IRF3, and NFKB are activated, and the senescence-associated secretory
phenotype (SASP) is expressed in the human hearts and mouse models of laminopathies. We also have
identified and defined the LMNA-associated domains (LADs) in human cardiac myocytes (CMs) and have shown
that LADs are shifted in laminopathies and regulate CpG methylation and gene expression. Moreover, we have
identified 711 DSBs (q<0.05) in the nDNA in the LMNA-deficient as compared to the wild-type (WT) CMs by
END-Sequencing (END-Seq). DSBs show a preponderance toward the protein-coding genes, which is consistent
with the role of the LMNA in defining the boundaries of TADs and TOP2B processing. Furthermore, we have
shown that deletion of the Mb21l1 gene, encoding CGAS, attenuates the phenotype in a mouse model of cardiac
laminopathies. Therefore, we logic that studying premature aging in laminopathies would provide insights into
the mechanisms that are shared with “normal” aging. The large effect sizes of the LMNA mutations would provide
a better resolution in discerning the deranged hallmarks of aging than the “normal” aging, whereby numerous
determinants, each with a small effect size, interact stochastically to induce aging. Thus, we propose to identify
and characterize the genome-wide DSBs in CMs, cardiac fibroblasts (CFs), and endothelial cells (ECs) in
laminopathies and the old WT mice by END-Seq, the former because of the involvement of multiple cell types in
laminopathies and the latter to assess the extension of the findings in laminopathies to “normal” aging. Likewise,
we propose to identify and characterize the sources of the CyDNA in CMs, CFs, and ECs in laminopathies by
CGAS ChIP-Seq. Moreover, we propose to determine the effects of genetic blockade of the STING1 on selected
hallmarks of aging and cardiac phenotype in laminopathies. The findings are expected to provide insights into
the molecular basis of premature CV aging in laminopathies and likely the hallmarks of “normal” aging.
由编码核的 LMNA 基因突变引起的核纤层蛋白病中的过早衰老综合征
包膜蛋白核纤层蛋白 A/C (LMNA) 是基因组不稳定性的典型例子,这是基因组不稳定的标志
“正常”衰老是主要表型,也是死亡和死亡的主要原因。
核纤层蛋白病和“正常”衰老的发病机制有几个共同的机制。
调节线粒体功能、端粒长度、营养感应、干细胞再生和自噬,
是“正常衰老”的典型特征。
在“正常”衰老中观察到核缺陷,LMNA 也调节多种表观遗传。
衰老调节因子,包括去乙酰化酶和组蛋白脱乙酰酶,此外,LMNA 对于基因组至关重要。
双链 DNA 断裂 (DSB) 的不稳定性、诱导和修复以及机械完整性
这些机制也是“正常”衰老的核心机制。
我们已经证明胞质 DNA (CyDNA) 感应蛋白 CGAS/STING1 被诱导,并且它们的
下游效应子 TBK1、IRF3 和 NFKB 被激活,衰老相关的分泌
表型(SASP)在人类心脏和小鼠核纤层蛋白病模型中也有表达。
识别并定义了人类心肌细胞 (CM) 中的 LMNA 相关结构域 (LAD),并显示
LAD 在核纤层蛋白病中发生转移并调节 CpG 甲基化和基因表达。
与野生型 (WT) CM 相比,LMNA 缺陷的 nDNA 中鉴定出了 711 个 DSB (q<0.05)
END 测序 (END-Seq) 显示蛋白质编码基因占优势,这是一致的。
LMNA 在定义 TAD 和 TOP2B 处理的边界方面的作用此外,我们还有。
研究表明,编码 CGAS 的 Mb21l1 基因的缺失会减弱小鼠心脏病模型的表型。
因此,我们认为研究核纤层蛋白病的过早衰老将有助于深入了解核纤层蛋白病。
LMNA 突变的巨大效应将提供与“正常”衰老相同的机制。
与“正常”衰老相比,在识别衰老的紊乱特征方面有更好的解决方案,因此许多
每个影响较小的决定因素随机相互作用以诱导衰老。
并表征了 CM、心脏成纤维细胞 (CF) 和内皮细胞 (EC) 中的全基因组 DSB
核纤层蛋白病和 END-Seq 的老 WT 小鼠,前者是因为多种细胞类型参与
核纤层蛋白病和后者评估核纤层蛋白病的研究结果扩展到“正常”衰老。
我们建议通过以下方法来识别和表征核纤层蛋白病中 CM、CF 和 EC 中 CyDNA 的来源:
此外,我们建议确定 STING1 的基因封锁对选定的影响。
这些发现有望为核纤层蛋白病的衰老和心脏表型的标志提供见解。
核纤层蛋白病中CV过早衰老的分子基础,也可能是“正常”衰老的标志。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ali J Marian其他文献
At the Source: Treating Heart Failure by Altering Muscle Motor Function Cardiac Myosin Activation: a Potential Therapeutic Approach for Systolic Heart Failure Commentary
从源头上:通过改变肌肉运动功能治疗心力衰竭心肌肌球蛋白激活:收缩性心力衰竭的潜在治疗方法评论
- DOI:
10.2310/jim.0b013e3182819ac6 - 发表时间:
2013-03-01 - 期刊:
- 影响因子:2.6
- 作者:
J. James;Jeffrey Robbins;Malik;Aruni Bhatnagar;Ali J Marian - 通讯作者:
Ali J Marian
A Highly Durable Rnai Therapeutic Inhibitor of Pcsk9 a New Approach to Pcsk9 Therapeutics Commentaries on Cutting Edge Science
Pcsk9 高度耐用的 Rnai 治疗抑制剂 Pcsk9 治疗的新方法 前沿科学评论
- DOI:
10.1073/pnas.83.2.474 - 发表时间:
1986 - 期刊:
- 影响因子:11.1
- 作者:
Fitzgerald;Nan Wang;Alan R Tall;Aruni Bhatnagar;Ali J Marian - 通讯作者:
Ali J Marian
Cardiac Regeneration
心脏再生
- DOI:
10.1371/journal.pone.0216297 - 发表时间:
2024-09-13 - 期刊:
- 影响因子:3.7
- 作者:
Francisco X. Galdos;Yuxuan Guo;Sharon L. Paige;Nathan J. VanDusen;Sean M. Wu;William T. Pu;Ali J Marian;Harvard Stem - 通讯作者:
Harvard Stem
Editorial: Gene-based renaming of human diseases.
社论:基于基因的人类疾病重命名。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:2.3
- 作者:
Ali J Marian - 通讯作者:
Ali J Marian
Inhibition of Mir-25 Improves Cardiac Contractility in the failing Heart Wahlquist Et Al R Ecent Work by Wahlquist Et Al Promise of Mirnas as Novel Therapeutic Targets Mirna-modulating Drugs Mir-25 in Heart Failure Commentaries on Cutting Edge Science
抑制 Mir-25 可改善衰竭心脏的心脏收缩力 Wahlquist 等人的近期工作 Wahlquist 等人承诺将 Mirna 作为新型治疗靶标 Mirna 调节药物 Mir-25 在心力衰竭中的应用 前沿科学评论
- DOI:
10.1007/s10753-016-0414-3 - 发表时间:
2015-10-26 - 期刊:
- 影响因子:0
- 作者:
E. Bush;E. van Rooij;Aruni Bhatnagar;Ali J Marian - 通讯作者:
Ali J Marian
Ali J Marian的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ali J Marian', 18)}}的其他基金
Cell type-Specific Therapeutic Targeting of canonical WNT Pathway in Arrhythmogenic Cardiomyopathy
致心律失常性心肌病典型 WNT 通路的细胞类型特异性治疗靶向
- 批准号:
10418626 - 财政年份:2020
- 资助金额:
$ 61.57万 - 项目类别:
Cell type-Specific Therapeutic Targeting of canonical WNT Pathway in Arrhythmogenic Cardiomyopathy
致心律失常性心肌病典型 WNT 通路的细胞类型特异性治疗靶向
- 批准号:
10594529 - 财政年份:2020
- 资助金额:
$ 61.57万 - 项目类别:
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations
LMNA 突变引起的扩张型心肌病 DNA 损伤的机制和治疗靶点
- 批准号:
10684002 - 财政年份:2016
- 资助金额:
$ 61.57万 - 项目类别:
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations
LMNA 突变引起的扩张型心肌病 DNA 损伤的机制和治疗靶点
- 批准号:
10221032 - 财政年份:2016
- 资助金额:
$ 61.57万 - 项目类别:
Pathogenic Role of Selected Cardiac Myocyte- and Fibroblast-Specific Epigenetic Changes in Laminopathies
选定的心肌细胞和成纤维细胞特异性表观遗传变化在核纤层蛋白病中的致病作用
- 批准号:
9119644 - 财政年份:2016
- 资助金额:
$ 61.57万 - 项目类别:
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations
LMNA 突变引起的扩张型心肌病 DNA 损伤的机制和治疗靶点
- 批准号:
10455102 - 财政年份:2016
- 资助金额:
$ 61.57万 - 项目类别:
Pathogenic Role of Selected Cardiac Myocyte- and Fibroblast-Specific Epigenetic Changes in Laminopathies
选定的心肌细胞和成纤维细胞特异性表观遗传变化在核纤层蛋白病中的致病作用
- 批准号:
9242688 - 财政年份:2016
- 资助金额:
$ 61.57万 - 项目类别:
Hypertrophy Regression with N-Acetylcysteine in Hypertrophic Cardiomyopathy
N-乙酰半胱氨酸治疗肥厚型心肌病的肥厚消退
- 批准号:
8590218 - 财政年份:2012
- 资助金额:
$ 61.57万 - 项目类别:
Hypertrophy Regression with N-Acetylcysteine in Hypertrophic Cardiomyopathy
N-乙酰半胱氨酸治疗肥厚型心肌病的肥厚消退
- 批准号:
8403983 - 财政年份:2012
- 资助金额:
$ 61.57万 - 项目类别:
Hypertrophy Regression with N-Acetylcysteine in Hypertrophic Cardiomyopathy
N-乙酰半胱氨酸治疗肥厚型心肌病的肥厚消退
- 批准号:
8240317 - 财政年份:2012
- 资助金额:
$ 61.57万 - 项目类别:
相似国自然基金
腺相关病毒载体介导的circ_12952基因治疗通过激活结直肠癌抗肿瘤免疫增强PD-1抗体疗效的机制研究及临床探索
- 批准号:82303073
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
聚合物囊泡靶向骨组织递送mRNA编码抗骨硬化蛋白单链抗体治疗骨质疏松的研究
- 批准号:82372442
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于抗原抗体相互作用的抗体定向虚拟设计与筛选
- 批准号:32370697
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CDK4/6抑制剂通过IFN/JAK/STAT1信号轴增强PD-1抗体抗肝细胞癌疗效的机制研究
- 批准号:82373313
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
P29单克隆抗体的3-羟基丁酰化修饰对其稳定性影响及提升抗泡型包虫病作用的研究
- 批准号:82360402
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Anti-medin immunotherapy for vascular aging and related dementias
针对血管老化和相关痴呆的抗 Medin 免疫疗法
- 批准号:
10724869 - 财政年份:2023
- 资助金额:
$ 61.57万 - 项目类别:
Does Vision Loss Affect Tauopathy in the Brain
视力丧失是否会影响大脑中的 Tau 蛋白病
- 批准号:
10670631 - 财政年份:2023
- 资助金额:
$ 61.57万 - 项目类别:
TWEAK/Fn14/UPR Signaling in Skeletal Muscle Wasting
骨骼肌萎缩中的 TWEAK/Fn14/UPR 信号转导
- 批准号:
10660397 - 财政年份:2023
- 资助金额:
$ 61.57万 - 项目类别:
Activation of endogenous progenitors via a nanoparticle-conjugated fibrous system to enhance meniscus repair
通过纳米颗粒共轭纤维系统激活内源祖细胞以增强半月板修复
- 批准号:
10607306 - 财政年份:2023
- 资助金额:
$ 61.57万 - 项目类别: